Immunic Stock Valuation

IMUX -  USA Stock  

USD 8.68  0.04  0.46%

Do you wonder what the value of Immunic is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Immunic, is its stock price multiplied by the total number of shares outstanding, calculating Immunic's enterprise value requires a different approach. It uses Immunic's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Free Cash Flow is likely to drop to about (49.9 M) in 2021. Enterprise Value is likely to drop to about 175.3 M in 2021.
Immunic retains a regular Real Value of $19.58 per share. The prevalent price of the firm is $8.68. At this time, the firm appears to be undervalued. Our model calculates the value of Immunic from evaluating the firm fundamentals such as Return On Asset of (34.74) %, return on equity of (76.76) %, and Shares Owned by Insiders of 24.60 % as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage acquiring undervalued assets and dropping overvalued assets since, at some point, asset prices and their ongoing real values will come together.

Immunic Valuation 

 
Refresh
Immunic Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Immunic's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today
8.68
27th of October 2021
Share
Please note that Immunic's price fluctuation is not too volatile at this time. Calculation of the real value of Immunic is based on 3 months time horizon. Increasing Immunic's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Immunic is useful when determining the fair value of the Immunic stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Immunic. Since Immunic is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunic Stock. However, Immunic's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
19.58
Real Value
23.62
Upside
Estimating the potential upside or downside of Immunic helps investors to forecast how Immunic stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunic more accurately as focusing exclusively on Immunic's fundamentals will not take into account other important factors:
Earnings
Estimates (7)
LowProjected EPSHigh
-4.34-3.91-3.34
Details
Hype
Prediction
LowEstimated ValueHigh
4.518.5512.59
Details
9 Analysts
Consensus
LowTarget PriceHigh
25.0052.5571.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Immunic's intrinsic value based on its ongoing forecasts of Immunic's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Immunic's closest peers. When choosing an evaluation method for Immunic, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Immunic Valuation Drivers Correlation

Many accounts on the financial statements of Immunic are highly interrelated and sometimes correlated. Consequently, when conducting Immunic's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Immunic
Click cells to compare fundamentals

Immunic Valuation Trend

Knowing Immunic's actual value is paramount for traders to make sound investment determinations. Immunic's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Immunic's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Immunic's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Immunic Market Cap

Immunic is currently regarded as number one stock in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 271.74 Million. Immunic totals roughly 189.22 Million in market capitalization claiming about 70% of stocks in Biotechnology industry.
Capitalization  Workforce  Valuation  Total debt  Revenue

Immunic Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Immunic's current stock value. Our valuation model uses many indicators to compare Immunic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunic competition to find correlations between indicators driving Immunic's intrinsic value. More Info.
Immunic is currently regarded as number one stock in price to earning category among related companies. It is currently regarded as number one stock in beta category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunic by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunic's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunic's earnings, one of the primary drivers of an investment's value.

About Immunic Valuation

The equity valuation mechanism determines the current worth of Immunic on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Immunic. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Immunic based exclusively on its fundamental and basic technical indicators. By analyzing Immunic's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Immunic's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Immunic. We calculate exposure to Immunic's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Immunic's related companies.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.

Immunic Quarterly Enterprise Value

152.73 MillionShare

Immunic Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Immunic does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio6.46
Enterprise Value To Ebitda-2.60

Immunic Current Valuation Indicators

Valuation refers to the process of determining the present value of Immunic and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Immunic we look at many different elements of the entity such as Immunic's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Immunic, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Immunic's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Immunic's worth.
Please see Risk vs Return Analysis. Note that the Immunic information on this page should be used as a complementary analysis to other Immunic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Immunic Stock analysis

When running Immunic price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.